NEW YORK, August 10, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: AstraZeneca PLC (NYSE: AZN), Valeant
Pharmaceuticals International Inc. (NYSE: VRX), Novartis A.G.
(NYSE: NVS), Heron Therapeutics Inc. (NASDAQ: HRTX) and Alkermes
PLC (NASDAQ: ALKS). Free research report on AstraZeneca can be
accessed at
https://www.EquityResearchInstitute.com/reports?keyword=AZN. On
Friday, August 07, 2015, the NASDAQ
Composite ended at 5,043.54, down 0.26%, the Dow Jones Industrial
Average lost 0.27%, to finish the day at 17,373.38 and the S&P
500 closed at 2,077.57, down 0.29%. The losses were broad based as
eight out of nine sectors ended the session in negative. Register
for your complimentary reports at the links given below.
AstraZeneca PLC's stock lost 1.61%, to close the day at
$33.69. The stock recorded a trading
volume of 3.27 million shares, above its three months average
volume of 2.67 million shares. Over the past three months and since
the start of this year, AstraZeneca PLC's shares have fallen by
3.63% and 1.58%, respectively. However, the stock has advanced
4.38% in the last one month. The company's shares are trading 1.21%
above their 50-day moving average. Additionally, AstraZeneca PLC
traded at a PE ratio of 71.68 and has a Relative Strength Index
(RSI) of 52.01. Sign up and read the free notes on AZN at:
https://www.EquityResearchInstitute.com/reports?keyword=AZN
On Friday, shares in Valeant Pharmaceuticals International Inc.
recorded a trading volume of 2.15 million shares, higher than their
three months average volume of 1.62 million shares. The stock ended
the day 0.25% lower at $247.79.
Shares of the company traded at a PE ratio of 101.97. Valeant
Pharmaceuticals International Inc.'s stock has surged 10.92% in the
last one month, 11.68% in the previous three months and 73.15% on
YTD basis. The company is trading above its 50-day and 200-day
moving averages by 4.26% and 30.45%, respectively. Furthermore,
shares of Valeant Pharmaceuticals International Inc. have an RSI of
52.10. The complimentary notes on VRX can be downloaded in PDF
format at:
https://www.EquityResearchInstitute.com/reports?keyword=VRX
Novartis AG's stock edged 0.12% lower, to close Friday's session
at $102.21. The stock recorded a
trading volume of 1.08 million shares, below its three months
average volume of 1.59 million shares. Over the last one month and
since the beginning of 2015, Novartis AG's shares have advanced
2.19% and 13.43%, respectively. However, the stock has lost 0.69%
in the previous three months. The company is trading 0.06% and
4.33% above its 50-day and 200-day moving averages, respectively.
Furthermore, Novartis AG's stock traded at a PE ratio of 25.88 and
has an RSI of 47.09. Register for free on Equity Research Institute
and access the latest research on NVS at:
https://www.EquityResearchInstitute.com/reports?keyword=NVS
Heron Therapeutics Inc.'s stock finished Friday's session 0.67%
higher at $31.58. A total of 0.70
million shares were traded, which was below its three months
average volume of 1.50 million shares. Over the last one month and
the previous three months, Heron Therapeutics Inc.'s shares have
surged 4.71% and 157.59%, respectively. Additionally, the stock has
rallied 213.92% since the beginning of 2015. The company's shares
are trading above their 50-day and 200-day moving averages by 3.98%
and 101.55%, respectively. Heron Therapeutics Inc.'s stock has an
RSI of 47.65. The complete research on HRTX is available for free
at:
https://www.EquityResearchInstitute.com/reports?keyword=HRTX
On Friday, shares in Alkermes PLC ended the session 0.80% lower
at $67.21. The stock reported a
trading volume of 0.82 million shares, below its three months
average volume of 0.96 million shares. Alkermes PLC's shares have
gained 7.81% in the last one month, 13.43% in the previous three
months and 14.77% on YTD basis. The company is trading 3.41% above
its 50-day moving average and 7.95% above its 200-day moving
average. Moreover, shares of Alkermes PLC have an RSI of 50.41.
Free in-depth research on ALKS is available at:
https://www.EquityResearchInstitute.com/reports?keyword=ALKS
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com